Key terms
About BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BEAM news
Apr 02
7:25pm ET
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
Apr 02
7:14pm ET
Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause
Apr 02
3:20pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 30
3:48pm ET
Is Beam Therapeutics Stock (NASDAQ:BEAM) Too Late to the Game?
Mar 28
6:12am ET
Korro Bio price target raised to $115 from $100 at H.C. Wainwright
Mar 26
1:25pm ET
Beam Therapeutics: A Strong Buy on Regulatory Clearance and Promising BEAM-302 Preclinical Data
Mar 26
6:20am ET
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Mar 01
1:08am ET
Beam Therapeutics: Financial and Clinical Prospects Inform Hold Rating
Feb 28
7:50am ET
Beam Therapeutics price target raised to $35 from $27 at RBC Capital
Feb 28
6:32am ET
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
Feb 28
6:13am ET
Beam Therapeutics files automatic mixed securities shelf
Feb 28
6:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
Feb 28
5:40am ET
Beam Therapeutics: Strong Buy Rating on Impressive Q4 Earnings and Promising Pipeline Developments
Feb 28
5:23am ET
Beam Therapeutics price target raised to $42 from $26 at Barclays
Feb 28
3:36am ET
Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)
Feb 27
1:56pm ET
William Blair Keeps Their Buy Rating on Beam Therapeutics (BEAM)
Feb 27
6:33am ET
Beam Therapeutics reports Q4 EPS $1.73, consensus ($1.01)
Jan 30
1:15pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Jan 30
10:55am ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Jan 15
2:25pm ET
Beam Therapeutics price target lowered to $66 from $95 at Stifel
Jan 09
9:25am ET
BMO Capital Sticks to Its Buy Rating for Beam Therapeutics (BEAM)
Jan 09
5:45am ET
Beam Therapeutics: A Strong Buy on Clinical Progress and Strategic Advancements
Jan 09
5:11am ET
Beam Therapeutics: A Strong Buy on SCD Clinical Progress and Robust Financial Position
No recent press releases are available for BEAM
BEAM Financials
Key terms
Ad Feedback
BEAM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BEAM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
